Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:23 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 6,440 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Completed No phase listed Observational

Correlation Between Glycated Hemoglobin and Mean Plasma Glucose in Hemodialysis Patients

NCT01634035
View directory record Official record
Conditions
ESRD
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 1 Interventional

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

NCT01182168
View directory record Official record
Conditions
Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
Interventions
gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Nov 1, 2026, 5:23 PM EST
Not listed Phase 2 Interventional

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

NCT02312050
View directory record Official record
Conditions
Diabetic Chronic Kidney Disease
Interventions
GCS-100, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Chula Vista, California • El Centro, California • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Nov 1, 2026, 5:23 PM EST
Terminated No phase listed Observational

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

NCT04125290
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Pueblo, Colorado • Bridgeton, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 2 Interventional

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

NCT00097955
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Nov 1, 2026, 5:23 PM EST
Enrolling by invitation Not applicable Interventional

Heterozygous Individuals for AGXT and Kidney Stones

NCT04430426
View directory record Official record
Conditions
Kidney Stone, Urolithiasis, Calcium Oxalate
Interventions
Controlled Diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 1, 2026, 5:23 PM EST
Terminated Phase 4 Interventional Results available

Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

NCT03821376
View directory record Official record
Conditions
Renal Malignant Tumor
Interventions
Contrast enhanced ultrasound with Lumason
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Nov 1, 2026, 5:23 PM EST
Completed Not applicable Interventional

Novel Strategies for Innovating Deceased Donor Procurement

NCT03007017
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Deceased donor nephrectomy, prior to cross clamp of donor aorta, Deceased donor nephrectomy, standard of care
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Nov 1, 2026, 5:23 PM EST
Completed Not applicable Interventional Results available

Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis

NCT00825318
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Ultrafiltration
Procedure
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 1 Interventional Results available

A Study of LY2928057 in Hemodialysis Participants

NCT01991483
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Kidney Disease, Chronic
Interventions
LY2928057, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Nov 1, 2026, 5:23 PM EST
Completed Not applicable Interventional

Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR

NCT02669966
View directory record Official record
Conditions
ESRD, Hepatitis C
Interventions
Kidney transplantation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Nov 1, 2026, 5:23 PM EST
Completed Not applicable Interventional

High Powered Stone Dusting vs. Fragmentation and Basketing at Time of Ureteroscopy

NCT05006937
View directory record Official record
Conditions
Kidney Stone, Ureteral Stone
Interventions
Dusting, Basket extraction
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 2 Interventional Results available

Phase II Study of Vandetanib in Individuals With Kidney Cancer

NCT00566995
View directory record Official record
Conditions
Renal Cancer, Von Hippel Lindau
Interventions
ZACTIMA (Vandetanib) (ZD6474)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 4 Interventional Results available

Empiric Versus Selective Prevention Strategies for Kidney Stone Disease

NCT05365477
View directory record Official record
Conditions
Kidney Stones, Nephrolithiasis
Interventions
Empiric Therapy: Diet, Empiric Therapy: Drug, Selective Therapy: Diet, Selective Therapy: Drug
Behavioral · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 1, 2026, 5:23 PM EST
Completed Not applicable Interventional Results available

Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients

NCT02409901
View directory record Official record
Conditions
Kidney Transplant
Interventions
Exercise Rehabilitation
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Nov 1, 2026, 5:23 PM EST
Terminated Phase 1 Interventional Results available

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

NCT03260504
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Aldesleukin, Pembrolizumab
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597584
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Nov 1, 2026, 5:23 PM EST
Suspended Phase 1 Interventional

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

NCT05967533
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer (AJCC) v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Fermented Wheat Germ Extract
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 4 Interventional Results available

Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy

NCT00526331
View directory record Official record
Conditions
Esophageal Diseases, Gastrointestinal Diseases, Disorder of the Genitourinary System, Gynecologic Diseases, Kidney Diseases, Liver Diseases, Pancreatic Diseases, Prostate Cancer, Spinal Disease
Interventions
Vigileo Monitor, FloTrac Sensor
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 3 Interventional Results available

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Nov 1, 2026, 5:23 PM EST
Completed No phase listed Observational

Diabetic Kidney Alarm (DKA) Study

NCT03128229
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Diabetic Ketoacidosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Nov 1, 2026, 5:23 PM EST
Withdrawn Phase 3 Interventional

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 1, 2026, 5:23 PM EST
Terminated Phase 1 Interventional

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

NCT00683553
View directory record Official record
Conditions
Acute Renal Failure, Acute Kidney Injury
Interventions
I5NP, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
21 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Nov 1, 2026, 5:23 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

NCT02836873
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fresno, California • La Palma, California • Lincoln, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Nov 1, 2026, 5:23 PM EST